Developing a vaccine targeting a key protein in influenza viruses
Germline targeting for neuraminidase broadly neutralizing antibodies
This study is working on a new flu vaccine that aims to help your body fight off different strains of the virus by using special antibodies that target a key part of the virus, making it easier for your immune system to recognize and respond to it.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11140166 on NIH RePORTER |
What this research studies
This research focuses on creating a broad-spectrum influenza vaccine by targeting neuraminidase, a protein that plays a crucial role in the virus's ability to infect cells. The approach involves using broadly neutralizing antibodies (bnAbs) that can bind to a conserved site on neuraminidase, which is typically difficult to access. By employing a technique called germline targeting, the researchers aim to enhance the immune response by priming rare precursor B cells that can develop into these effective antibodies. The study will evaluate promising bnAb candidates and utilize advanced protein engineering methods to design immunogens that can stimulate a robust immune response against various influenza strains.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of influenza infection, particularly those with compromised immune systems or underlying health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already been vaccinated with existing vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective influenza vaccine that provides broader protection against multiple strains of the virus.
How similar studies have performed: Other research has shown promise in using similar approaches to enhance vaccine efficacy, particularly in targeting conserved viral proteins.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Steichen, Jon — Scripps Research Institute, the
- Study coordinator: Steichen, Jon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.